BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34856172)

  • 1. Effectiveness and Tolerance of Renin-Angiotensin System Inhibitors With Aging in Chronic Kidney Disease.
    Villain C; Metzger M; Liabeuf S; Hamroun A; Laville S; Mansencal N; Combe C; Fouque D; Frimat L; Jacquelinet C; Laville M; Ayav C; Briançon S; Pecoits-Filho R; Hannedouche T; Stengel B; Massy ZA;
    J Am Med Dir Assoc; 2022 Jun; 23(6):998-1004.e7. PubMed ID: 34856172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
    Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
    Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study.
    Leon SJ; Whitlock R; Rigatto C; Komenda P; Bohm C; Sucha E; Bota SE; Tuna M; Collister D; Sood M; Tangri N
    Am J Kidney Dis; 2022 Aug; 80(2):164-173.e1. PubMed ID: 35085685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
    Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
    Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort Study.
    Fu EL; Clase CM; Evans M; Lindholm B; Rotmans JI; Dekker FW; van Diepen M; Carrero JJ
    Am J Kidney Dis; 2021 May; 77(5):719-729.e1. PubMed ID: 33246024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detrimental effect of renin-angiotensin blockade on progression of chronic kidney disease at later stages: A matter of dosage adjustment?
    Caravaca-Fontán F; Valladares J; Díaz-Campillejo R; Barroso S; Luna E; Caravaca F
    Nefrologia (Engl Ed); 2020; 40(1):38-45. PubMed ID: 31196659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Acute Increases in Plasma Creatinine after Renin-Angiotensin Blockade with Subsequent Outcomes.
    Fu EL; Trevisan M; Clase CM; Evans M; Lindholm B; Rotmans JI; van Diepen M; Dekker FW; Carrero JJ
    Clin J Am Soc Nephrol; 2019 Sep; 14(9):1336-1345. PubMed ID: 31395593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials.
    Xie X; Liu Y; Perkovic V; Li X; Ninomiya T; Hou W; Zhao N; Liu L; Lv J; Zhang H; Wang H
    Am J Kidney Dis; 2016 May; 67(5):728-41. PubMed ID: 26597926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renin-Angiotensin System Inhibitors in Patients With COVID-19: A Meta-Analysis of Randomized Controlled Trials Led by the International Society of Hypertension.
    Gnanenthiran SR; Borghi C; Burger D; Caramelli B; Charchar F; Chirinos JA; Cohen JB; Cremer A; Di Tanna GL; Duvignaud A; Freilich D; Gommans DHF; Gracia-Ramos AE; Murray TA; Pelorosso F; Poulter NR; Puskarich MA; Rizas KD; Rothlin R; Schlaich MP; Schreinlecher M; Steckelings UM; Sharma A; Stergiou GS; Tignanelli CJ; Tomaszewski M; Unger T; van Kimmenade RRJ; Wainford RD; Williams B; Rodgers A; Schutte AE;
    J Am Heart Assoc; 2022 Sep; 11(17):e026143. PubMed ID: 36000426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Higher Quality of Care on Initiation of Long-term Dialysis in Patients With CKD and Diabetes.
    Wu HY; Fukuma S; Shimizu S; Norton EC; Tu YK; Hung KY; Chen MR; Chien KL; Fukuhara S
    Am J Kidney Dis; 2017 Nov; 70(5):666-674. PubMed ID: 28764919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.
    Linde C; Bakhai A; Furuland H; Evans M; McEwan P; Ayoubkhani D; Qin L
    J Am Heart Assoc; 2019 Nov; 8(22):e012655. PubMed ID: 31711387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse effects during treatment with renin-angiotensin-aldosterone system inhibitors; should we stay or should we stop?
    Leon SJ; Carrero JJ
    Curr Opin Nephrol Hypertens; 2023 May; 32(3):290-296. PubMed ID: 36811640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Changes in Creatinine and Potassium Levels After Initiation of Renin Angiotensin Aldosterone System Inhibitors With Emergency Department Visits, Hospitalizations, and Mortality in Individuals With Chronic Kidney Disease.
    Garlo KG; Bates DW; Seger DL; Fiskio JM; Charytan DM
    JAMA Netw Open; 2018 Nov; 1(7):e183874. PubMed ID: 30646338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stopping renin-angiotensin system inhibitors after hyperkalemia and risk of adverse outcomes.
    Xu Y; Fu EL; Trevisan M; Jernberg T; Sjölander A; Clase CM; Carrero JJ
    Am Heart J; 2022 Jan; 243():177-186. PubMed ID: 34610282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
    Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
    JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade.
    Lin CC; Wu YT; Yang WC; Tsai MJ; Liu JS; Yang CY; Li SY; Ou SM; Tarng DC; Hsu CC
    PLoS One; 2017; 12(12):e0189126. PubMed ID: 29216260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No increase in adverse events during aliskiren use among ontario patients receiving angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers.
    Gilbert CJ; Gomes T; Mamdani MM; Hellings C; Yao Z; Garg AX; Wald R; Harel Z; Juurlink DN
    Can J Cardiol; 2013 May; 29(5):586-91. PubMed ID: 23541666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescription of renin-angiotensin system blockers and risk of acute kidney injury: a population-based cohort study.
    Mansfield KE; Nitsch D; Smeeth L; Bhaskaran K; Tomlinson LA
    BMJ Open; 2016 Dec; 6(12):e012690. PubMed ID: 28003286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of angiotensin-converting enzyme inhibitors or receptor blockers on post-ICU discharge outcome in patients with acute kidney injury.
    Gayat E; Hollinger A; Cariou A; Deye N; Vieillard-Baron A; Jaber S; Chousterman BG; Lu Q; Laterre PF; Monnet X; Darmon M; Leone M; Guidet B; Sonneville R; Lefrant JY; Fournier MC; Resche-Rigon M; Mebazaa A; Legrand M;
    Intensive Care Med; 2018 May; 44(5):598-605. PubMed ID: 29766216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Underprescription of renin-angiotensin system blockers in moderate to severe chronic kidney disease.
    Shirazian S; Grant CD; Mujeeb S; Sharif S; Kumari P; Bhagat M; Mattana J
    Am J Med Sci; 2015 Jun; 349(6):510-5. PubMed ID: 26030613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.